A first for Temple University Hospital and U.S. Patients MINNEAPOLIS, June 10, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, the first interventional COPD trial to target reduction in COPD exacerbations as a primary endpoint. Two U.S. patients were successfully treated […]
3750 Annapolis Lane North
Minneapolis, MN 55447
© 2019 Nuvaira Inc. All rights reserved.
Nuvaira Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).